Prof. Jing Li | Cardiovascular Disease | Best Researcher Award

 Prof. Jing Li, beijing chaoyang hospital, China

Dr. Jing Li, PhD, is an Associate Professor at the Heart Center & Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. A distinguished researcher in cardiovascular disease, she has made groundbreaking contributions to understanding the role of gut microbiota in hypertension and cardiovascular diseases. Dr. Li is a Youth member of the China Association for the Promotion of International Healthcare Exchanges and holds several key roles in cardiovascular physiology and vascular medicine groups. Her research, supported by the National Natural Science Foundation and Beijing Science Foundation, focuses on the pathological mechanisms and prevention of cardiovascular diseases. She has published over 28 SCI papers, significantly advancing knowledge in hypertension, gut microbiota, and cardiovascular pathophysiology.

Professional Profile

orcid

Jing Li, PhD – Suitability for the Research for Best Researcher Award

Jing Li, PhD, Associate Professor at the Heart Center and Beijing Chaoyang Hospital, Capital Medical University, is an exemplary candidate for the Research for Best Researcher Award due to her pioneering contributions in cardiovascular research, particularly in the role of gut microbiota in hypertension and cardiovascular diseases. With a robust track record of presiding over major research projects such as those funded by the National Natural Science Foundation and Beijing Science Foundation, Dr. Li’s research addresses critical gaps in understanding the pathophysiology of hypertension through the lens of intestinal bacteria, offering innovative insights into disease prevention and management. Her work in elucidating the causal relationship between gut microbiota and hypertension is ground-breaking, highlighting the potential of microbiota as therapeutic targets in managing cardiovascular diseases.

Her impressive body of work includes 28 SCI papers published in high-impact journals such as Hypertension, Microbiome, and Gut Microbes, with a total impact factor of 175.8. Dr. Li’s published research on the dysbiosis of gut microbiota in hypertensive patients and its implications for cardiovascular health has had a profound impact on the field, particularly with publications like “Gut microbiota dysbiosis contributes to the development of hypertension” (Microbiome, 2017) and “Causality of Opportunistic Pathogen Klebsiella pneumoniae to Hypertension Development” (Hypertension, 2022).

Education 

Dr. Jing Li earned her PhD in Cardiovascular Physiology and Pathophysiology, specializing in hypertension and gut microbiota interactions. She pursued her academic journey at renowned institutions in China, where she honed her expertise in cardiovascular research and microbiology. Dr. Li’s academic background lays the foundation for her groundbreaking research on how the intestinal microbiome contributes to cardiovascular health. Her research interests reflect her commitment to advancing scientific knowledge in this critical field, with particular focus on the development of innovative preventive strategies against hypertension. Throughout her career, Dr. Li has also been involved in several collaborative projects with national research agencies, further enriching her knowledge and professional development.

  Professional Experience 

Dr. Jing Li holds a prominent role at Beijing Chaoyang Hospital, where she leads significant cardiovascular research projects, particularly focusing on hypertension and gut microbiota. She has presided over several high-impact national projects, such as those funded by the National Natural Science Foundation and Beijing Science Foundation. As an associate professor and director of the China Medical and Microecology Integration Alliance, Dr. Li combines her leadership in academia with a strong commitment to practical, clinical applications of her research. Her position as a youth member of the China Association for the Promotion of International Healthcare Exchanges further underscores her influence in advancing international collaborations in cardiovascular health. She is also a deputy leader of the Cardiovascular Physiology and Pathophysiology Group of the Vascular Medicine Committee of the Beijing Physiological Science Society, shaping the future of cardiovascular medicine through innovation and education.

 Awards and Recognition

Dr. Jing Li’s exceptional research and contributions to cardiovascular disease have earned her recognition from various prestigious organizations. She has been awarded multiple honors for her work on hypertension, gut microbiota, and cardiovascular diseases. Her leadership in national research projects has led to a significant body of work that has been recognized globally. Dr. Li’s publications, with over 175.8 impact factors, are considered seminal in the field of cardiovascular disease and microbiome research. She has been invited to share her insights at several international conferences and has received numerous accolades for her innovative approach to tackling hypertension and other cardiovascular disorders. Her recognition extends to her roles as a director and expert advisor to national health organizations, where she provides valuable guidance on advancing the integration of medical research with practical healthcare solutions.

Research Skill On Cardiovascular Disease

Dr. Jing Li possesses advanced research skills in cardiovascular physiology, pathophysiology, and microbiome studies. She is an expert in exploring the connections between gut microbiota and cardiovascular diseases such as hypertension, a field where her work has opened new avenues for disease prevention. Her methodological expertise spans experimental design, microbiological analysis, and advanced statistical modeling. Dr. Li’s research combines cutting-edge laboratory techniques with clinical data, enabling her to bridge the gap between basic science and real-world health applications. She has demonstrated an exceptional ability to identify novel biomarkers, explore microbial mechanisms, and validate therapeutic targets for cardiovascular diseases. Her work integrates molecular biology, microbiology, and clinical medicine, positioning her as a leading researcher in her field. Dr. Li’s contributions to cardiovascular research are highly regarded, influencing the direction of future research in hypertension and related cardiovascular conditions.

Publication Top Notes

• BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome

  • Authors: Yang Shen, Ying Dong, Jie Jiao, Pan Wang, Mulei Chen, Jing Li
  • Citation: Vaccines, 2023

• Alterations of gut viral signals in atrial fibrillation: complex linkage with gut bacteriome

  • Authors: Zuo, Kun; Li, Jing; Fang, Chen; Zhong, Jiuchang; Xu, Li; Yang, Xinchun
  • Citation: Aging, 2022

• Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients

  • Authors: Dong, Ying; Wang, Pan; Jiao, Jie; Yang, Xinchun; Chen, Mulei; Li, Jing
  • Citation: Frontiers in Cell and Developmental Biology, 2022

• Causality of Opportunistic Pathogen Klebsiella pneumoniae to Hypertension Development

  • Authors: Li, Jing; Gao, Qiannan; Ma, Yiyangzi; Deng, Yue; Li, Shuangyue; Shi, Na; Niu, Haitao; Liu, Xin-Yu; Cai, Jun
  • Citation: Hypertension, 2022

• Characterization of fecal metabolome changes in patients with obstructive sleep apnea

  • Authors: Dong, Ying; Wang, Pan; Lin, Junling; Han, Chunming; Jiao, Jie; Zuo, Kun; Chen, Mulei; Yang, Xinchun; Cai, Jun; Jiang, He et al.
  • Citation: Journal of Clinical Sleep Medicine, 2022

• Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination

  • Authors: Jiao, Jie; Shen, Yang; Wang, Pan; Zuo, Kun; Yang, Xinchun; Chen, Mulei; Dong, Ying; Li, Jing
  • Citation: Frontiers in Bioscience-Landmark, 2022

• Kidney microbiota dysbiosis contributes to the development of hypertension

  • Authors: Liu, Xin-Yu; Li, Jing; Zhang, Yamei; Fan, Luyun; Xia, Yanli; Wu, Yongyang; Chen, Junru; Zhao, Xinyu; Gao, Qiannan; Xu, Bing et al.
  • Citation: Gut Microbes, 2022

• Potential of gut microbiota for lipopolysaccharide biosynthesis in European women with type 2 diabetes based on metagenome

  • Authors: Dong, Ying; Wang, Pan; Yang, Xinchuan; Chen, Mulei; Li, Jing
  • Citation: Frontiers in Cell and Developmental Biology, 2022

• Profile of gut flora in hypertensive patients with insufficient sleep duration

  • Authors: Jiao, Jie; Dong, Ying; Wang, Pan; Zuo, Kun; Han, Chunming; Cai, Jun; Zhong, Jiuchang; Yang, Xinchun; Li, Jing
  • Citation: Journal of Human Hypertension, 2022

• Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19

  • Authors: Li, Xue-Ting; Zhang, Mi-Wen; Zhang, Zhen-Zhou; Cao, Yu-Dan; Liu, Xiao-Yan; Miao, Ran; Xu, Yuan; Song, Xiao-Fang; Song, Jia-Wei; Liu, Ying et al.
  • Citation: International Journal of Cardiology, 2021